has been cited by the following article(s):
[1]
|
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
Vaccines,
2021
DOI:10.3390/vaccines9080894
|
|
|
[2]
|
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
Gynecologic Oncology,
2016
DOI:10.1016/j.ygyno.2016.09.018
|
|
|